8th Annual ALS TDI Leadership Summit
Thursday, November 1 2012
9:00 am – 5:00 pm
This event was posted by ALS Therapy Development Institute
Location: Sheraton Boston
Registration & Light Refreshment
9:00AM - 12:00PM
Title: Immune Modulation as a Therapeutic Strategy for ALS
By: Steve Perrin, Ph.D.
Affiliation(s): CEO & Chief Scientific Officer, ALS TDI (USA)
Title: Propagated Protein Misfolding in ALS: A Target for Effective Therapy
By: Neil Cashman, M.D.
Affiliation(s): Co-Founder & Chief Scientific Officer & Co-Founder, Amorfix Life Sciences, Director, ALS Centre, University of British Columbia (Canada)
Title: Update on ALS Genetics: Pathways, Prognoses and Prospects
By: Robert Brown, M.D., Ph.D.
Affiliation(s): Chair & Professor, Department of Neurology, University of Massachusetts Medical School (USA)
Title: Neuromuscular Junction Stability in ALS
Affiliation(s): Neurotune AG (Switzerland)
2012 Leadership Awards Presentation
Click here to nominate someone!
Iris Löw-Friedrich, M.D., Ph.D.
Executive VP Global Projects and Development & Chief Medical Officer, UCB SA
Mark Namchuk, Ph.D.
Senior Vice President of Research, Vertex Pharmaceuticals
John McKew, Ph.D.
Chief, NIH Center for Translational Therapeutics to Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS)
Vice President of Innovation & Networks, Kauffman Foundation
Steve Perrin, Ph.D.
CEO & Chief Scientific Officer, ALS TDI
Panel Moderated by: Amy Dockser Marcus, Staff Reporter, The Wall Street Journal
4P:00M - 6:00PM
Cocktail and Networking Reception